Literature DB >> 21075399

Super selective radio embolization of the porcine kidney with 90yttrium resin microspheres: a feasibility, safety and dose ranging study.

Simon MacKie1, Suresh de Silva, Peter Aslan, Leigh Ladd, Michelle Houang, David Cade, Warwick Delprado.   

Abstract

PURPOSE: We determined whether super selective radio embolization of the porcine kidney was technically feasible and evaluated histopathological changes in the treatment target zone (upper or lower renal pole), adjacent nontargeted kidney, and adjacent and distant organs after administering (90)Y labeled vs bland resin microspheres.
MATERIALS AND METHODS: We performed super selective radio embolization with (90)Y resin microspheres in 1 kidney and with an equivalent number of bland microspheres in the corresponding pole of the contralateral kidney as a control. The aim was to achieve radio embolization of a target zone equivalent to approximately a third of the kidney volume. A pathologist independently graded macroscopic and microscopic changes in the kidney, and adjacent and distant tissue resulting from incremental increases (0.15 to 0.35 GBq) in implanted activity in 6 pigs.
RESULTS: We recorded grade 4 histological changes in the treatment target zone (upper or lower renal pole) in 5 of 6 pigs after injecting (90)Y resin microspheres with evidence of nephron sparing effects in the adjacent renal tissue at the lowest activity. At activity greater than 0.3 GBq increasing damage was noted to adjacent renal tissue beyond the treatment target zone. No toxicity was evident in adjacent or distant organs.
CONCLUSIONS: Delivery of highly targeted intra-arterial radiotherapy to the kidney is feasible and safe in the pig model. Further evaluation is warranted as a potential treatment for advanced renal cell carcinoma or for localized disease in patients who are not candidates for surgery.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21075399     DOI: 10.1016/j.juro.2010.09.001

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers.

Authors:  Rita Golfieri
Journal:  Hepat Oncol       Date:  2014-09-09

Review 2.  Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives.

Authors:  Cristina Mosconi; Alberta Cappelli; Cinzia Pettinato; Rita Golfieri
Journal:  World J Hepatol       Date:  2015-04-18

3.  [Irreversible electroporation: the new generation of local ablation techniques for renal cell carcinoma].

Authors:  U-B Liehr; J J Wendler; S Blaschke; M Porsch; A Janitzky; D Baumunk; M Pech; F Fischbach; D Schindele; C Grube; J Ricke; M Schostak
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

4.  Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5 % glucose during administration.

Authors:  Hojjat Ahmadzadehfar; Carsten Meyer; Claus Christian Pieper; Ralph Bundschuh; Marianne Muckle; Florian Gärtner; Hans Heinz Schild; Markus Essler
Journal:  EJNMMI Res       Date:  2015-10-13       Impact factor: 3.138

5.  Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer.

Authors:  Wouter Bult; Stephanie G C Kroeze; Mattijs Elschot; Peter R Seevinck; Freek J Beekman; Hugo W A M de Jong; Donald R A Uges; Jos G W Kosterink; Peter R Luijten; Wim E Hennink; Alfred D van het Schip; J L H Ruud Bosch; J Frank W Nijsen; Judith J M Jans
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

Review 6.  Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.

Authors:  Alberta Cappelli; Cinzia Pettinato; Rita Golfieri
Journal:  J Hepatocell Carcinoma       Date:  2014-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.